Authors
Latest:
Investigational Agents for Relapsed/Refractory MyelomaKeith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Latest:
Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine TrialKeith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLLKellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Latest:
Dr. Bailey Discusses the Treatment of Pediatric Patients With SarcomaKelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.
Latest:
Choosing a Care Model and Making It WorkIn June, CMS selected roughly 200 medical oncology practices to participate in the public payer’s own flavor of oncology payment reform: the Oncology Care Model. This program, which launched in July, is designed to lower costs and improve quality of care for treatment episodes that start with a six-month chemotherapy regimen.
Latest:
Improving Colorectal Cancer Screening Rates Among African AmericansColorectal cancer is the third leading cause of cancer death among African Americans. The CRC mortality rate among African Americans is 29.8% compared with 19.5% among Caucasians.
Latest:
Frontline Venetoclax/Obinutuzumab Combo Emerges as Treatment Option for CLL With CKTOthman Al-Sawaf, MD, discusses findings from the CLL14 trial, the rationale for exploring this proposed combination, and shares his thoughts on the emerging treatment paradigms in chronic lymphocytic leukemia.
Latest:
Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast CancerKelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.
Latest:
Novel Molecular Test Contributes to Definitive Diagnosis in MelanomaThe Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.
Latest:
Dr. Hunt on Treating Local Regional Recurrence in Breast CancerKelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.
Latest:
Payers Still Denying Coverage Despite Clinical Trial MandateA mandate enacted after the 2010 Patient Protection and Affordable Care Act was supposed to improve health coverage for patients enrolled in clinical trials; however, nearly 63% of cancer centers and organizations that responded to a recent survey reported insurance denials of routine care costs associated with patient involvement in clinical trials during 2014.
Latest:
Urologists Will Need Training in Immuno-Oncology Adverse EventsAs immunotherapy has become increasingly utilized, urologists are more frequently participating in the management of patients who are receiving immunotherapy.
Latest:
Dr McCann on Navigating Work-Life Balance As a Woman in OncologyKelly E. McCann, MD, PhD, discusses her experiences with mentorship and work-life balance as a woman in oncology.
Latest:
Dr. Paulson Discusses Acquired Resistance to ImmunotherapyKelly Paulson, MD, fellow, Seattle Cancer Care Alliance, discusses acquired resistance to immunotherapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
Latest:
Dr. Moses On Ongoing Trials in mHSPCKelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Kernstine on Variation in Thoracic Surgery OutcomesDr. Kemp Kernstine from University of Texas, Southwestern Medical Center Discusses Variation in Thoracic Surgery Outcomes
Latest:
Dr. Yoneda Discusses Pulmonary NodulesDr. Ken Y. Yoneda from UC Davis Cancer Center Discusses Pulmonary Nodules
Latest:
Stereotactic Body Radiotherapy Shows Potential in Oligometastatic CancerAn increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.
Latest:
Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CMLKendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.
Latest:
Dr. Anderson on Addressing Unmet Needs in Myeloma With Descartes-11Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.
Latest:
University of Wisconsin Team Develops Novel Strategy for High-Risk NeuroblastomaInvestigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.
Latest:
Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple MyelomaKenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Latest:
Dr. Fleisher Discusses Monitoring Patients With ONJDr. Ken Fleisher from New York University Discusses Monitoring Patients With ONJ
Latest:
Dr Shain on the Evolving Role of Bispecific Antibodies in Multiple Myeloma ManagementKenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.
